Oncology
4 drugs are in development for Lung Cancer.
- Companies
- 3
- Clinical trials
- 109
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Lung Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Preclinical(1)
| Drug | Company |
|---|---|
| suba-itraconazole | Inhibitor Therapeutics, Inc. (INTI) |
Phase 1/Phase 2(3)
About this indication
Lung Cancer context
Oncology·MeSH: Lung Neoplasms (D008175)
Narrower concept of MeSH descriptor Lung Neoplasms
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Lung Cancer?
BioSniper tracks 4 drugs in development for Lung Cancer across 3 companies.
How many clinical trials target Lung Cancer?
There are 109 clinical trials targeting Lung Cancer tracked by BioSniper.
What is the prevalence of Lung Cancer?
The estimated prevalence of Lung Cancer is approximately 75.0 per 100,000 population.